The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
29 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $15,767,166 in first-year total cost, median $578,670.
Most frequent study sections
- Special Emphasis Panel[ZRG1 CTH-E (55)]9
- Special Emphasis Panel[ZRG1 OTC-N (55)]9
- Special Emphasis Panel[ZRG1 OTC1-J (55)]8
- Special Emphasis Panel[ZRG1 CTH-B (55)]3
Most frequent institutions
- BAYLOR COLLEGE OF MEDICINE3
- UNIVERSITY OF ALABAMA AT BIRMINGHAM2
- UT SOUTHWESTERN MEDICAL CENTER2
- WEILL MEDICAL COLL OF CORNELL UNIV2
- BETH ISRAEL DEACONESS MEDICAL CENTER1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2024 | Cross-species development and credentialing of pediatric AML models1R01CA285272-01 | KLCO, JEFFERY MMAGEE, JEFFREY ALAN | WASHINGTON UNIVERSITY, MO | $665,385 | ZRG1 |
| 2024 | Construction of A Lung Cancer Preclinical Model Cross-comparison Platform1R01CA285336-01 | CAI, LING | UT SOUTHWESTERN MEDICAL CENTER, TX | $627,833 | ZRG1 |
| 2024 | Culture of tumor versus normal cells1R01CA285335-01 | INCE, TAN A. | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $364,140 | ZRG1 |
| 2024 | Defining Cancer Intervention Targets by Functional Genomics Analysis of Outbred F1 Mice1R01CA278818-01A1 | JACOB, JENNIFER BKIDDER, BENJAMIN L | WAYNE STATE UNIVERSITY, MI | $88,693 | ZRG1 |
| 2023 | Understanding the cellular and functional changes in the immune tumor microenvironment of glioblastoma during progression and treatments.1R01CA271601-01A1 | BOUSSIOTIS, VASSILIKI ACHAREST, ALAINVERHAAK, ROEL GW | BETH ISRAEL DEACONESS MEDICAL CENTER, MA | $672,634 | ZRG1 |
| 2023 | Genetically engineered mouse model to improve therapy of NUT carcinoma1R01CA285308-01 | FRENCH, CHRISTOPHER AKESKIN, DERIN BSHAPIRO, GEOFFREY I | BRIGHAM AND WOMEN'S HOSPITAL, MA | $672,468 | ZRG1 |
| 2023 | "Novel Mouse Models for Quantitative Understanding of Baseline and Therapy-Driven Evolution of Prostate Cancer Metastasis"1R01CA272466-01A1 | NOWAK, DAWID GRZEGORZ | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $657,652 | ZRG1 |
| 2023 | In vivo prime editing for precision cancer mouse models1R01CA275945-01A1 | XUE, WEN | UNIV OF MASSACHUSETTS MED SCH WORCESTER, MA | $625,607 | ZRG1 |
| 2023 | preclinical optimization of BCMA directed T cell therapy1R01CA272426-01A1 | BERGSAGEL, PETER LEIFCHESI, MARTA | MAYO CLINIC ARIZONA, AZ | $621,878 | ZRG1 |
| 2023 | Optimizing Syngeneic Mouse Models to Target Mutant p531R01CA278089-01A1 | LI, YONG | BAYLOR COLLEGE OF MEDICINE, TX | $596,803 | ZRG1 |
| 2023 | Clinical, molecular, and immune characterization of naturally occurring osteosarcoma in dogs1U01CA281905-01 | REBHUN, ROBERT B | UNIVERSITY OF CALIFORNIA AT DAVIS, CA | $584,628 | ZRG1 |
| 2023 | A new mouse model for studying the pathogenesis and immunobiology of intrahepatic cholangiocarcinoma and improving its immunotherapy1R01CA281784-01 | KARIN, MICHAEL | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $563,902 | ZRG1 |
| 2022 | Gamma delta T cell based melanoma therapies1R01CA258113-01A1 | HERLYN, MEENHARD FXU, XIAOWEI | UNIVERSITY OF PENNSYLVANIA, PA | $666,701 | ZRG1 |
| 2022 | Site-specific Integration of Large (10-100 kb) DNA Constructs into the Mouse Genome and Human Induced Pluripotent Stem Cells Using the Cas9-Bxb1 Integrase Toolbox1R01CA265978-01A1 | HOSUR, VISHNU | JACKSON LABORATORY, ME | $646,321 | ZRG1 |
| 2022 | Credentialing next-generation human glioma models for precision therapeutics1R01CA258248-01A1 | FURNARI, FRANKMILLER, CHRISTOPHER RYANO'ROURKE, DONALD M | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $618,530 | ZRG1 |
| 2022 | Next Generation Rat Models of ER+ Breast Cancer1R01CA271498-01 | LI, YIZHANG, XIANG | BAYLOR COLLEGE OF MEDICINE, TX | $612,175 | ZRG1 |
| 2022 | Escape from CAR T surveillance through lineage plasticity1R01CA269269-01 | ERNST, PATRICIAFRY, TERRY J. | UNIVERSITY OF COLORADO DENVER, CO | $578,670 | ZRG1 |
| 2022 | Loss of NF1 drives hormone dependent mammary carcinogenesis in a rat model with intact immune system1R01CA265933-01A1 | KESTERSON, ROBERT AWALLIS-SCHULTZ, DEEANN | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $547,183 | ZRG1 |
| 2022 | Polymerase epsilon-based mouse and derived organoid models of intestinal cancer1R01CA265884-01 | CASTRILLON, DIEGO H | UT SOUTHWESTERN MEDICAL CENTER, TX | $493,934 | ZRG1 |
| 2022 | Engineering Large Chromosomal Deletions in Mice to Advance Precision Oncology1R01CA261949-01A1 | CHEN, MING | DUKE UNIVERSITY, NC | $416,540 | ZRG1 |
| 2021 | Investigation of the role of epithelial-mesenchymal plasticity in renal cell carcinoma1R01CA258226-01 | GENOVESE, GIANNICOLA | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $591,326 | ZRG1 |
| 2021 | Credentialing Models of Invasive Lobular Breast Cancer for Translational Research1R01CA252378-01A1 | LEE, ADRIAN VOESTERREICH, STEFFI | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $573,041 | ZRG1 |
| 2021 | New mouse model of cisplatin-induced AKI and development of prevention therapy1R01CA251141-01A1 | ZHAO, JIANJUN | CLEVELAND CLINIC LERNER COM-CWRU, OH | $560,614 | ZRG1 |
| 2021 | Lentiviral-Induced Swine Model of Spinal Cord Glioma1R01CA251393-01A1 | BOULIS, NICHOLAS MCANOLL, PETER | EMORY UNIVERSITY, GA | $541,702 | ZRG1 |
| 2021 | Improving the translational value of head and neck cancer patient-in-mouse models1R37CA255330-01A1 | KIMPLE, RANDALL J. | UNIVERSITY OF WISCONSIN-MADISON, WI | $520,953 | ZRG1 |
| 2021 | Canine MHC-I genotyping and tumor specific neoantigen determination1R01CA252713-01A1 | HILDEBRAND, WILLIAMZHAO, SHAYING | UNIVERSITY OF GEORGIA, GA | $492,039 | ZRG1 |
| 2021 | Comparative modeling of sarcoma microenvironments for the discovery of biomarkers and tumor vulnerabilities1R01CA258265-01 | GUARNERIO, JLENIA | CEDARS-SINAI MEDICAL CENTER, CA | $443,656 | ZRG1 |
| 2021 | Epigenetically Engineered Mouse Model for Lung Cancer Therapy1R01CA261723-01 | SHEN, LANLAN | BAYLOR COLLEGE OF MEDICINE, TX | $365,308 | ZRG1 |
| 2021 | Development of 3-dimensional human pituitary corticotroph tumor cultures as a preclinical model for drug discovery1R01CA251930-01A1 | HEANEY, ANTHONY P | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $356,850 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.